<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307215</url>
  </required_header>
  <id_info>
    <org_study_id>10-3436</org_study_id>
    <nct_id>NCT01307215</nct_id>
  </id_info>
  <brief_title>TAP Block: Does Volume Make a Difference?</brief_title>
  <official_title>Lumbar Transversus Abdominal Plane (TAP) Block: Does Volume Make a Difference?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have abdominal surgery will experience pain from the incision. The lumbar TAP
      block is a procedure used to reach the nerve endings in the abdominal wall so that there is a
      reduction in pain after surgery. Using ultrasound guidance, a solution of ropivacaine will be
      injected after surgery. The aim of this study is to determine the effect of changes in the
      volume of the injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain from a surgical incision happens in most patients. During the perioperative period, the
      use of the TAP block has been shown to reduce pain scores, opioid consumption and sedation
      scores. Also, there is a trend towards a reduction of post-operative nausea and vomiting. The
      aim of the block is to reach the distal nerve endings of the abdominal wall from T6 to L1
      dermatomes using ultrasound guidance with a single shot of ropivacaine at different volumes.
      Currently, there is consensus about optimal procedure-specific volumes and local anesthetic
      concentrations for lumbar TAP blocks. This is a pilot study and the purpose being is it
      feasible to do a large scale clinical study to determine the influence of increasing the
      local anesthetic volume.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the feasibility of a large scale clinical study to determine the influence on increasing the local anesthetic volume.</measure>
    <time_frame>6 month</time_frame>
    <description>This will be shown as a number and a percenttage of patients recruited and randomized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Using ice and pinprick, determine the dermatomal block distribution at 2,6,12,24 and 48 hours post block.</measure>
    <time_frame>48 hours</time_frame>
    <description>The assessor will measure the extend of the block distribution at the various time intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at 2,6,12,24, and 48 hours post-block.</measure>
    <time_frame>48 hours</time_frame>
    <description>Using a visual analog scale, patient pain scores will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-controlled analgesia opioid requirements at 2,6,12,24 and 48 post-block.</measure>
    <time_frame>48 hours</time_frame>
    <description>Record drug consumption at the time intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative nausea and vomiting at 2,6,12,24, and 48 hours.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Block failure rate.</measure>
    <time_frame>48 hours</time_frame>
    <description>Block failure rate is defined as the lack of any sensory block following the TAP block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's overall satisfaction.</measure>
    <time_frame>48 hours</time_frame>
    <description>Using a LIKERT score, patient satisfaction will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge time from PACU.</measure>
    <time_frame>24 hours</time_frame>
    <description>The time in which the patient is discharged from the recovery room.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>20mLs of 0.5% ropivacaine per side</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>30mLs of 0.33% ropivacaine per side</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40mLs of 0.25% ropivacaine per side</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>20mLs of 0.5%</description>
    <arm_group_label>20mLs of 0.5% ropivacaine per side</arm_group_label>
    <other_name>naropeine</other_name>
    <other_name>naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>30mLs of 0.33%</description>
    <arm_group_label>30mLs of 0.33% ropivacaine per side</arm_group_label>
    <other_name>naropeine</other_name>
    <other_name>naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>40mLs of 0.25%</description>
    <arm_group_label>40mLs of 0.25% ropivacaine per side</arm_group_label>
    <other_name>naropeine</other_name>
    <other_name>naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years old

          -  total abdominal hysterectomy

          -  capable of completing informed consent

          -  no previous chronic opioid use

          -  no previous abdominal wall surgeries

        Exclusion Criteria:

          -  patient refusal

          -  contraindication to regional anesthesia: coagulopathy, anticoagulant use, bleeding
             disorders,

          -  local or systemic infection

          -  local anesthetic allergy

          -  BMI&gt;35
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Forero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University/St. Joseph's Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Petersen PL, Mathiesen O, Torup H, Dahl JB. The transversus abdominis plane block: a valuable option for postoperative analgesia? A topical review. Acta Anaesthesiol Scand. 2010 May;54(5):529-35. doi: 10.1111/j.1399-6576.2010.02215.x. Epub 2010 Feb 17. Review.</citation>
    <PMID>20175754</PMID>
  </reference>
  <reference>
    <citation>Carney J, McDonnell JG, Ochana A, Bhinder R, Laffey JG. The transversus abdominis plane block provides effective postoperative analgesia in patients undergoing total abdominal hysterectomy. Anesth Analg. 2008 Dec;107(6):2056-60. doi: 10.1213/ane.0b013e3181871313.</citation>
    <PMID>19020158</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>April 23, 2013</last_update_submitted>
  <last_update_submitted_qc>April 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAP block</keyword>
  <keyword>incision pain</keyword>
  <keyword>total hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

